Capital Advisors Wealth Management LLC Has $1.24 Million Position in Novo Nordisk A/S (NYSE:NVO)

Capital Advisors Wealth Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 8.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,691 shares of the company’s stock after buying an additional 720 shares during the quarter. Capital Advisors Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,244,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Salvus Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 18.7% during the 1st quarter. Salvus Wealth Management LLC now owns 2,646 shares of the company’s stock valued at $340,000 after purchasing an additional 416 shares during the last quarter. Strong Tower Advisory Services grew its holdings in Novo Nordisk A/S by 3.0% during the 1st quarter. Strong Tower Advisory Services now owns 22,765 shares of the company’s stock worth $2,904,000 after acquiring an additional 657 shares during the last quarter. Strategic Planning Group LLC bought a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $1,450,000. Doliver Advisors LP bought a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $1,383,000. Finally, Harbor Investment Advisory LLC grew its holdings in Novo Nordisk A/S by 110.9% during the 1st quarter. Harbor Investment Advisory LLC now owns 1,858 shares of the company’s stock worth $239,000 after acquiring an additional 977 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Argus upped their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Stock Up 3.0 %

NVO traded up $4.26 during trading on Tuesday, hitting $146.54. 1,853,877 shares of the company’s stock were exchanged, compared to its average volume of 4,441,270. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $133.31 and its two-hundred day moving average is $122.37. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $146.75. The stock has a market cap of $657.60 billion, a P/E ratio of 50.28, a PEG ratio of 1.41 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.